Exelixis | EXEL - Ingresos Por Ventas





Ventas Cambio Fecha
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.29B 213M 2026-03
Bayer EUR 13.41B 1.97B 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Cytokinetics USD 19.35M 1.59M 2026-03
Eisai JPY 205.43B 14.51B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Exelixis USD 610.8M 12.14M 2026-03
Genmab DKK 1.06B 36M 2025-12
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.27B 240M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.29B 110M 2026-03
Moderna USD 389M 289M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 13.11B 226M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.14B 65M 2026-03
Takeda JPY 1.09T 100B 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Xencor USD 4.51M 23.73M 2026-03